Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
There is no evidence of a characterized gene, protein, or functional product called "PIMREG pseudogene 3." The established gene **PIMREG** (Phosphatidylinositol binding clathrin assembly protein interacting mitotic regulator, also known as FAM64A) is a regulatory protein involved in mitotic progression and is upregulated in various cancers[1][2]. However, "PIMREG pseudogene 3" is not cataloged in major gene databases, nor is it featured in research or review literature regarding pseudogenes with regulatory or disease relevance. Pseudogenes are generally copies of protein-coding genes that have lost the potential to code for functional proteins, although some may retain regulatory or rare coding roles[3][5]. There are no data supporting "PIMREG pseudogene 3" as such an entity. **Note:** If you seek information about the functional PIMREG gene itself or general pseudogene biology, further information is available, but for "PIMREG pseudogene 3" specifically, there appears to be a likely naming or data error, or this is a not-well-characterized entity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on PIMREG pseudogene 3 (PIMREGP3).